# EDGAR Filing Document

**Accession Number:** 0001816815
**File Stem:** 0001493152-26-006960
**Filing Date:** 2026-2
**Character Count:** 19165
**Document Hash:** dfaa4e626c92a42bed4506da086cc3fa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-006960.hdr.sgml**: 20260217

**ACCESSION NUMBER**: 0001493152-26-006960

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260217

**FILED AS OF DATE**: 20260217

**DATE AS OF CHANGE**: 20260217

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bon Natural Life Ltd
- **CENTRAL INDEX KEY:** 0001816815
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40517
- **FILM NUMBER:** 26636897

**BUSINESS ADDRESS:**
- **STREET 1:** ROOM 601, BLOCK C, GAZELLE VALLEY, NO.69
- **STREET 2:** JINYE ROAD, HIGH-TECH ZONE, XIAN
- **CITY:** SHAANXI
- **STATE:** F4
- **ZIP:** 710076
- **BUSINESS PHONE:** 0086-29-88346301

**MAIL ADDRESS:**
- **STREET 1:** ROOM 601, BLOCK C, GAZELLE VALLEY, NO.69
- **STREET 2:** JINYE ROAD, HIGH-TECH ZONE, XIAN
- **CITY:** SHAANXI
- **STATE:** F4
- **ZIP:** 710076

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

**Commission File Number 001-40517**

**BON NATURAL LIFE LIMITED**

(Translation of registrant's name into English)

**Room 601, Block C, Gazelle Valley, No.69, Jinye Road**

**High-Tech Zone, Xi'an, Shaanxi, China**

**People's Republic of China**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

**Note**: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 ****

**Framework Cooperation Agreement**

On January 22, 2026, our subsidiary Xi'an App-Chem Bio (Tech) Co., Ltd ("App-Chem") entered into entered into a Framework Cooperation Agreement (the "Agreement") with Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. ("Chang'an Pilot").

Pursuant to the Agreement, App-Chem and Chang'an Pilot have agreed to jointly establish an integrated innovation chain encompassing fundamental research through to industrial application. The parties will co-establish the "BON & Pilot Natural Ingredients and Biomanufacturing Joint Laboratory," which will focus on research related to AI-driven biomanufacturing of natural ingredients. The parties also intend to jointly establish an engineering center to promote process development, pilot-scale verification, and industrial application of outcomes generated from the joint laboratory and other cooperative initiatives.

The Agreement further contemplates comprehensive strategic collaboration in areas including technology research and development, market expansion, and capital partnership, as well as potential capital collaboration through industrial funds, investment activities, mergers and acquisitions, restructuring, and technology-driven financial mechanisms.

The term of the Agreement is three years, and specific matters regarding the cooperation will be stipulated in separate formal agreements to be entered into by both parties. The Agreement may be terminated by either party with three months' prior notice or by mutual agreement.

The foregoing is a summary of the material terms of the Agreement. The Agreement contains additional terms, covenants and conditions and should be reviewed in its entirety for additional information.

**Exhibits**

The following exhibits are included in this Form 6-K:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 10.1 | [Translation of Framework Cooperation Agreement with Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd.](ex10-1.htm) |
| 99.1 | [Press Release dated February 17, 2026](ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: February 17, 2026 | **Bon Natural Life Limited** | **Bon Natural Life Limited** |
|  | By: | */s/ Yongwei Hu* |
|  |  | Yongwei Hu |
|  |  | Chairman and Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**SHAANXI CHANG'AN Pilot LIFE SCIENCE INDUSTRY INNOVATION CENTER CO., LTD.**

**AND**

**XI'AN APP-CHEM BIO (TECH) CO., LTD.**

**FRAMEWORK COOPERATION AGREEMENT**

**Party A:** Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd.

**Address:** Room 310, 3rd Floor, Block F, Central and Western Land Port Financial Town, No. 99 Gangwu Avenue, International Trade & Logistics Park, Xi'an City, Shaanxi Province, China

**Telephone:** +86-29-87389679

**Postal Code:** 710026

**Party B:** Xi`an App-Chem Bio (Tech) Co., Ltd.

**Address:** Room 601, Building C, Entrepreneurship R&D Park, 69 Jinye Road, High-tech Zone, Xi'an City, Shaanxi Province, China

**Telephone:** +86-29-88346301

**Postal Code:** 710077

**I. Overview of Partners**

**Party A:** Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd.

Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. (hereinafter referred to as "Pilot Life Science"), a wholly-owned subsidiary of Shaanxi Chang'an Pilot Industry Innovation Center Co., Ltd., was established on 11 October 2022 with a registered capital of RMB 7,000,000. The Company focuses its research and development efforts on future-oriented life science industries, with a particular emphasis on cell and gene therapy. It is dedicated to advancing breakthroughs in frontier technologies such as cell and gene technology, synthetic biology, and biological breeding, and to promoting the integration of new medical services with technologies including 5G/6G, the metaverse, and artificial intelligence. Furthermore, the Company is engaged in the development of high-end medical equipment incorporating advanced technologies such as digital twins and brain-computer interfaces, concentrating on generic technologies, cutting-edge innovations, modern engineering technologies, and disruptive technological advancements. Leveraging Shaanxi's robust life science innovation resources and well-established biomedical industry chain, the Company collaborates with universities, medical institutions, and enterprises to closely align with market and clinical demands. Adopting a product-oriented approach, it facilitates the market-driven integration, establishment, and upgrading of laboratories, engineering (technology) R&D centers, GMP pilot platforms, clinical R&D centers, and related facilities. Through this strategy, the Company achieves the sustained output of new pharmaceuticals, medical devices, equipment, and technologies.

**Party B:** Xi`an App-Chem Bio (Tech) Co., Ltd. (NASDAQ: BON)

Founded in 2006, Xi`an App-Chem Bio (Tech) Co., Ltd., (hereinafter referred to as "App-Chem"), is a global leading supplier specializing in the biomanufacturing of natural active ingredients and AI-powered health solutions. The company, publicly traded on the NASDAQ under the ticker symbol BON, currently operates across key markets including North America, the European Union, China, Japan, and South Korea.

**II. Background on the Collaboration**

Amidst the nationwide drive to advance the "Healthy China" initiative and actively foster a "Community with a Shared Future for Mankind," the health and wellness industry stands at a historic moment of growth, with technological innovation emerging as the pivotal force behind its transformation. Recognizing this industry trend and building upon a synergistic partnership that combines complementary business resources, technological expertise, and market presence—a partnership forged through long-term collaboration and unwavering mutual trust—the two parties have entered into this strategic cooperation agreement. Driven by a shared commitment to promoting global health through advanced biomanufacturing and the modernization of Traditional Chinese Medicine, the Parties have, following extensive and constructive consultations, jointly established the terms of cooperation set forth herein.

**III. Scope of Collaboration**

**(1) Joint Development of R&D Platforms and Industrial Transformation Systems**

The Parties hereby agree to jointly establish an integrated innovation chain encompassing fundamental research through to industrial application. Specifically, they shall utilize the existing laboratory space and equipment of App-Chem to co-establish the "BON & Pilot Natural Ingredients and Biomanufacturing Joint Laboratory." The Joint Laboratory will primarily conduct research on AI-driven biomanufacturing of natural ingredients possessing significant strategic value. Furthermore, based on the aforementioned collaboration, the Parties shall jointly establish an engineering center dedicated to promoting process development, pilot-scale verification, and industrial application of outcomes generated from the Joint Laboratory as well as other cooperative initiatives. This collaboration is aimed at realizing both the economic value and societal benefits derived from scientific and technological achievements.

**(2) Launching Joint Technological Initiatives and Ecosystem Partnerships**

The Parties hereby agree to engage in comprehensive strategic collaboration based on aligned strategic objectives, encompassing key areas including but not limited to technology research and development, market expansion, and capital partnership. This cooperation shall extend to, without limitation: joint R&D initiatives in sectors such as innovative traditional Chinese medicine and biopharmaceuticals; integration of both Parties' platforms, technologies, channels, and intellectual resources to jointly promote the global market presence of TCM products and services; and exploration of capital collaboration through means including the establishment of industrial funds, investment activities, mergers and acquisitions, restructuring, and technology-driven financial mechanisms—thereby leveraging capital as a catalyst to accelerate innovation and industrial integration.

**IV. Term**

Party A and Party B shall jointly establish a laboratory, with the term of cooperation being three years. Specific matters regarding the cooperation between the parties shall be stipulated in a separate formal agreement to be entered into by both parties. Three months prior to the expiration of the term of this Agreement, the parties may decide whether to renew it upon mutual consultation. Either party may terminate this Agreement in advance by providing the other party with a three-month prior notice, and this Agreement may be terminated upon mutual agreement by the parties.

**V. Confidentiality**

Both parties shall maintain the confidentiality of the cooperation matters and shall not disclose, reveal, or provide to any third party any confidential information obtained from or through the other party without prior written consent. Neither party shall provide the content of this Agreement to any third party in any form, or use it for purposes such as business solicitation or publicity, without the other party's consent. Upon termination of this Agreement, each party shall, in accordance with the requirements of the cooperation agreement, return or destroy all confidential materials in its possession. In the event that either party discloses the content of the cooperation matters and causes losses to the other party, the non-breaching party shall have the right to require the breaching party to indemnify for all losses incurred.The confidentiality obligations under this Clause shall survive the cancellation, rescission, or termination of this Agreement and shall remain in effect until the relevant confidential business information becomes part of the public domain.

**VI. MISCELLANEOUS**

1) Both Parties hereto shall keep confidential all information related to the cooperation, including but not limited to any and all contracts, technical data, and technical know-how, and shall not disclose the same to any third party without the prior written consent of the other Party.

2) Except as expressly required for the performance of work under this Agreement, neither Party shall use or reproduce the other Party's business information, technology, or other materials without the prior written permission of the other Party.

3) This Agreement serves only as a guideline for the cooperation between the Parties. The specific terms, conditions, rights, and obligations pertaining to any particular collaborative project shall be exclusively governed by a separate project-specific agreement executed by the Parties.

4) Any matters not covered herein shall be resolved through mutual consultation between the Parties. Any amendment, modification, or supplement to this Agreement shall be made in writing and duly executed by both Parties.

5) This Agreement is executed in quadruplicate, with each Party holding two original copies. It shall become effective upon the signatures of the authorized representatives of both Parties and the affixation of their respective official seals or contract seals.

Please check and advise the signature date below for further processing.[END OF TEXT]

(This page is intentionally left for signatures)

**Party A:** Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd.

**Legal Representative:**

**or Authorized Signature:**

**Date:** 

**Party B:** Xi`an App-Chem Bio (Tech) Co., Ltd.

**Legal Representative:**

**or Authorized Signature:**

**Date:**

## Exhibit 99.1

**Exhibit 99.1**

**BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing**

XI'AN, China - Feb. 17, 2026 — Bon Natural Life Limited (Nasdaq: BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech Co., Ltd., and Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. ("Chang'an Pilot").

The Joint Laboratory will focus on the research and development of bio-manufactured natural active ingredients for use in functional foods and personal care products. Through the integration of fermentation-based biosynthesis, natural compound isolation, and artificial intelligence-enabled process optimization, the Joint Laboratory is intended to support the Company's efforts to improve production efficiency, supply reliability, and environmental sustainability compared to traditional plant-based extraction methods.

Founded in 2006, BON operates in the development, manufacturing, and commercialization of natural active ingredients for applications in health and personal care products. The Company's product portfolio includes plant-derived extracts, functional food ingredients, and personal care actives. BON serves customers in China, North America, the European Union, Japan, South Korea, and other international markets.

BON possesses technical capabilities in natural ingredient extraction, separation, and biosynthesis, supported by a proprietary artificial intelligence-enabled bio-manufacturing research and development platform designed to integrate data analytics and process engineering for scalable production.

Chang'an Pilot, established in 2022, provides laboratory infrastructure and research services focused on life sciences and artificial intelligence-enabled manufacturing technologies.

Yongwei Hu, Chairman of BON, stated, "We believe the establishment of this Joint Laboratory will strengthen our research capabilities and create meaningful collaboration between our respective teams. We expect this initiative will support our continued efforts to develop scalable, high-quality natural ingredients and advance our long-term growth strategy."

**About Bon Natural Life Limited ("BON")**

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company's website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu \| IR

Email: bonnatural@appchem.cn

**Safe Harbor Statement**

This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.